Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 10/20 | 0.57 |
| ▸ | JAK3 | P52333 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
| ▸ | JAK1 | P23458 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 1/20 | 0.52 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.50 |
| ▸ | BCR | P11274 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899494 | 0.91 | SYK (0.57) | SYKJAK3LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4903370 | 0.89 | SYK (0.59) | SYKJAK2METALKABL1 | |
| SCHEMBL4902913 | 0.87 | ABL1 (0.57) | JAK3ALDH1A1HTTJAK2JAK1 | |
| SCHEMBL4896431 | 0.87 | ABL1 (0.52) | SYKABL1BCR | |
| SCHEMBL4901650 | 0.86 | DRD2 (0.52) | SYKHTTABL1BCR | |
| SCHEMBL4897217 | 0.86 | ABL1 (0.68) | SYKJAK3JAK2JAK1ABL1 | |
| SCHEMBL13924584 | 0.84 | SYK (0.53) | SYKJAK3LMNASMN1; SMN2ALDH1A1 | |
| SCHEMBL4900241 | 0.84 | SYK (0.53) | SYKLMNAALDH1A1JAK2 | |
| SCHEMBL8349109 | 0.83 | JAK2 (0.61) | SYKJAK3ALDH1A1HTTJAK2 | |
| SCHEMBL4900317 | 0.82 | DRD2 (0.51) | SYKLMNASMN1; SMN2ALDH1A1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | claimed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | claimed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | claimed |
| US-20080187575-A1 | Pyrimidine Derivatives | VICHEM CHEMIE KFT (HU) | 2008-08-07 | — | — | US | disclosed |
| EP-1786781-A2 | PYRIMIDINE DERIVATIVES | GPC Biotech AG (DE) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006021458-A2 | PYRIMIDINE DERIVATIVES | GPC BIOTECH AG (DE) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080187575-A1 | Pyrimidine Derivatives | TYMP, TDP1, PNP | SYK 2145/4885JAK3 902/4885LMNA 1955/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.